Moneycontrol
HomeNewsBusinessStartupExclusive | Dailyhunt in talks with Alpine Capital for $25 million funding  round

Exclusive | Dailyhunt in talks with Alpine Capital for $25 million funding  round

The regional language news and content aggregator has seen its numbers go up during the lockdown, say sources.

April 14, 2020 / 12:55 IST
Story continues below Advertisement
Representative image

Regional language news and content aggregator Dailyhunt is in talks to close a $25-million funding round led by Alpine Capital, a US-based private equity fund and a rare investor in Indian firms, sources said.

Dailyhunt has been in the market to raise $100 million for a year now, but is now settling for a smaller round after multiple discussions, including with the SoftBank Vision Fund, did not result in a deal. The fundraising is important for the startup ecosystem as well which has been hit hard by the coronavirus pandemic.

Story continues below Advertisement

“Alpine issued the term sheet when India was just beginning the shutdown. It is certainly odd for a virtual first-time investor to come in during a time like this. But Dailyhunt stands to benefit from the virus pandemic and lockdown because more people are consuming their content sitting at home than ever before,” said one of the sources who didn’t wish to be identified.

Dailyhunt and Alpine did not respond to Moneycontrol's queries seeking comments.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show